发明名称 |
Dendritic cell based cancer medicine using M. tuberculosis Rv0652 protein as an adjuvant |
摘要 |
PURPOSE: A dendritic cell cancer therapeutic agent using M. tuberculosis Rv0652 is provided to effectively suppress tumor growth. CONSTITUTION: A dendritic cell cancer therapeutic agent is manufactured by adding M. tuberculosis Rv0652 to immature dendritic cells. Rv0652 is recombinant Rv0652(rEC-Rv0652) expressed in E.coli. The recombinant Rv0652 is produced by amplifying with a forward primer of sequence number 1 and a reverse primer of sequence number 2. The dendritic cell cancer therapeutic agent is prepared by culturing Rv0652 for 20-30 hours. |
申请公布号 |
KR101290230(B1) |
申请公布日期 |
2013.07.30 |
申请号 |
KR20110010165 |
申请日期 |
2011.02.01 |
申请人 |
|
发明人 |
|
分类号 |
A61K38/10;A61K39/39;A61P35/00 |
主分类号 |
A61K38/10 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|